17,261 trials
Metastatic Urothelial Carcinoma · Bladder Cancer
Primary: Count of Participants With Response Measured by RECIST 1.1 — 16 Participants
Metastatic Colorectal Cancer
Primary: Disease Stabilisation Rate — 0 Participants
Leiomyosarcoma · Liposarcoma · Soft Tissue Sarcoma Adult
Primary: The Objective Response Rate (ORR) Based on RECIST 1.1 — 6 Participants
Malaria, Vivax
Primary: Safety of the PvDBPII-Matrix M1 Vaccine Candidate, Assessed Through Collection of Data on the Frequency, Duration and Severity of Solicited and Unsolicited Adverse…
Alzheimer Disease
Primary: Change From Baseline in Neuropsychiatric Inventory Clinician Version (NPI-C) Sum of Agitation and Aggression Domain Scores (NPI-C A+A) at Day 43: Analyzed Under Estimand…
SARS-CoV-2 Infection · COVID-19 · SARS-CoV-2 Acute Respiratory Disease
Primary: All Parts - Percentage of Participants Reporting Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) — 19; 20; 17; 19…
Psoriasis
Primary: PASI 75 - Week 12 (EoT) — 4; 4; 1; 46 Participants — p=0.161
Primary Aldosteronism
Primary: Change in Aldosterone-to-renin Ratio — -15.0; -7.0; -14.0; -11.8 ng*L/dL*mU — p=<0.0001
Oligodendroglioma · Oligoastrocytoma
Primary: Progression-free Survival (PFS) at Six Months (PFS6m) — 21 Percentage of participants
Metabolic Syndrome
Primary: Waist Circumference (WC) — 98.9; 102.1 cm
Non-small Cell Lung Cancer
Primary: Percentage of Participants Who Preferred Atezolizumab SC to Atezolizumab IV Assessed Using Patient Preference Questionnaire (PPQ) — 71.67; 69.84; 70.73 percentage of…
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Primary: Confirmed Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR) — 28.8 Percentage of Participants
Clear-cell Metastatic Renal Cell Carcinoma
Primary: Freedom From Progression at 6 Months — 58.5 Percentage
Temporomandibular Joint Disorders
Primary: Pain Score — 4.9; 4.4 units on a scale
Staphylococcus Aureus Bacteremia
Primary: Number of Participants Who Experienced Dose-limiting Toxicities — 0; 0; 0; 0 participants